Dynasty Wealth Management LLC Sells 3,206 Shares of Eli Lilly and Company $LLY

Dynasty Wealth Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 77.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 924 shares of the company’s stock after selling 3,206 shares during the period. Dynasty Wealth Management LLC’s holdings in Eli Lilly and Company were worth $705,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Laurel Wealth Advisors LLC lifted its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $8,827,714,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Franklin Resources Inc. boosted its stake in Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after acquiring an additional 564,736 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock worth $898,238,000 after purchasing an additional 536,679 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s sofetabart mipitecan for certain platinum‑resistant ovarian cancers — a meaningful validation for Lilly’s oncology pipeline that diversifies revenue beyond GLP‑1 drugs and could accelerate development/partnering value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: Phase results: Lilly’s Taltz combined with Zepbound showed superior results in a landmark psoriatic‑arthritis trial — suggests label expansion and additional commercial upside for existing franchises. Eli Lilly’s Taltz and Zepbound combo delivers superior results
• Positive Sentiment: Analyst/media bullishness: Several outlets (MarketBeat, The Motley Fool) highlight Lilly as a top play in 2026 because Zepbound and Mounjaro drive rapid growth and the company has late‑stage assets (Alzheimer’s, oncology, CV) that could sustain upside. That framing supports multiple expansion narratives. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
• Positive Sentiment: Longer‑term growth thesis reinforced: The Motley Fool argues 2026 could be “the year of Eli Lilly,” pointing to the company’s weight‑loss portfolio (recent quarter ~ $10B) and upcoming catalysts — a narrative that attracts growth investors. Prediction: 2026 Will Be the Year of Eli Lilly
• Neutral Sentiment: Analyst note: Guggenheim trimmed its price target slightly (from $1,163 to $1,161) but kept a “buy” rating — a minor technical change that maintains analyst bullishness and implies continued upside from current levels. LLY price target lowered by Guggenheim
• Neutral Sentiment: Takeover speculation calmed: Reports that Lilly might bid for Abivax circulated, but Abivax’s CEO dismissed the rumors as “noise,” removing an M&A upside narrative (so neutral-to-cooling for any takeover-driven pop). Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
• Neutral Sentiment: Industry comparison pieces (Zacks, Blockonomi) reiterate Lilly’s strength from Mounjaro/Zepbound and note an oral GLP‑1 near approval — these are context pieces that support the growth story but also flag competitive dynamics to watch. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Negative Sentiment: Competitive risk: Novo Nordisk’s new oral Wegovy pill showed very fast initial prescriptions after launch, and analysts note rising competition as oral formulations and other entrants scale — a development that could pressure Lilly’s market share and future growth if its oral GLP‑1 underperforms or is delayed. Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research note on Monday, November 10th. Five research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,040.95 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a 50 day moving average price of $1,053.86 and a 200-day moving average price of $875.14. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market capitalization of $984.09 billion, a PE ratio of 50.93, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.